Clinuvel Pharmaceuticals (ADR) (CUVL)
Commercializes SCENESSE® for adult EPP and develops melanocortin therapies.
Something off on this page? Send us feedback.
Sells SCENESSE®, an implant for adult EPP, through a controlled network of trained treatment centers, while developing afamelanotide, ACTH, peptide-delivery, and PhotoCosmetic programs. Revenue rests substantially on SCENESSE® and access relies on reimbursement arrangements.
Commercializes SCENESSE® (afamelanotide), a photoprotective implant for adults with erythropoietic protoporphyria, through trained and accredited treatment centers. The biopharmaceutical business directly manages orders, pricing, reimbursement support, and center relationships while outside suppliers manufacture, package, and distribute the drug. Its operating model keeps formulation research, clinical-study design, regulatory affairs, pharmacovigilance, and quality assurance in-house.
Develops SCENESSE® for vitiligo alongside NEURACTHEL®, PRÉNUMBRA®, VLRX-L, and CYACÊLLE PhotoCosmetics. Commercial activity is concentrated in North America and Europe, and SCENESSE® supplies substantially all sales. Access depends on insurer authorization and public reimbursement, while CUVL is a secondary Nasdaq ADS listing and the primary ordinary-share listing remains on the ASX.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Not reported.
HistoryDividendAnnual yield
No ownership filings on record for this listing.
- Disc Medicine
Late-stage oral EPP therapy for the same phototoxicity patients.
- Incyte
Approved repigmentation therapy for nonsegmental vitiligo.
- AVITA Medical
One-time device-based repigmentation for stable vitiligo.
- ANI Pharmaceuticals
Established ACTH therapy in the planned NEURACTHEL category.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Clinuvel Pharmaceuticals (ADR) | $5.89 | +1.51% | $292.5M | — | — | — | +5.9% |
| Disc Medicine | $68.29 | −0.30% | $2.63B | — | — | — | — |
| Incyte | $125.46 | +0.65% | $25.27B | 15.9 | 52.0 | 4.3 | +37.7% |
| AVITA Medical | $11.57 | +6.73% | $269.3M | — | — | 3.6 | +78.6% |
| ANI Pharmaceuticals | $77.69 | −1.47% | $1.79B | 17.0 | 8.3 | 1.8 | +25.9% |
| Median | 16.5 | 30.1 | 3.6 | +37.7% |